Revolutionizing Diabetes and Obesity Care
The global rise in Type 2 diabetes and obesity has spurred a growing demand for innovative health solutions, particularly GLP-1, GGG, and GIPR agonists. Our Forecast projections indicate that the GLP-1 market could reach $70 billion by 2030, underscoring the need for innovative supply and manufacturing solutions. Despite the MENA region's GLP-1 market featuring lower-end pricing, it remains attractive due to high diabetes and obesity prevalence, with Saudi Arabia securing a significant 35% market share. Currently, there are 105 products in the pipeline for GLP-1, GGG, GIPR agonists, with companies like Novo Nordisk, Zealand Pharma, Eli Lilly and Company, and Gmax Bio pharm leading the way in substantial pipelines for these health solutions.
The Role of Big Data in Enhancing Pharmaceutical R&D Efficiency
Sep, 2024
Learn about the integration of diverse data sources, the use of advanced data management tools, and the role of AI and machine learning in extracting actionable insights.
Revolutionizing Drug Development: The Impact of AI and Data Science in Pharma
Mar, 2024
This blog delves into the integration of AI technologies like machine learning and natural language processing in pharmaceutical processes, spotlighting their role in accelerating drug discovery, optimizing clinical trials, and personalizing patient care.
The MENA Opportunity: Navigating Market Dynamics for Spanish Pharmaceutical Growth
Apr, 2024
Delve into the MENA pharmaceutical market's unique dynamics and uncover growth strategies for Spanish pharmaceutical companies.